The Ameliorating Effect of Ipragliflozin, a SGLT2 lithobitor, on Liver Function Without Dependence on the Body Weight Reduction

Journal of the Japan Diabetes Society

Volumn 59, Issue 12, 2016, Pages 782-790

  Uchida, Junko ^a   Kabeya, Yusuke ^b   Oikawa, Yoichi ^a   Tanaka, Hajime ^a   Atsumi, Yoshihiro ^a   Osawa, Masaya ^a   Katsuki, Takeshi ^a   Kawai, Toshihide ^a  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008164839     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yang XP, Lai D, Zhnng XY, Shen HP, Huang YL (2014) Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 70: 1149-1158
2. Del Prato S, Nauck M, Duran-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, Parikh S (2015) Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 17: 581-590
3. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233
4. Kaku K, Inoue S, Matsuoka 0, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S (2013) Efficacy and safety of dapagliflozin as a mono-therapy for type 2 diabetes mellitus in Japanese patieiits with iHadequate glycacuHo coHtrol: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15: 432-440
5. Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Sako A, Mishima S, Yanai H (2016) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis. J Clin Med Res 8: 237-243
6. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y (2016) Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Pa-tients Irrespective of Body Weight Reduction. PLoS One 11: e0151511
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel 5, Mattheus M, Devins T, Johansen OE, Wo erle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373: 2117-2128
8. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR (2010) Ran domized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51
9. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fuji moto K, Chayama K, Saibara T (2012) Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicnfrr large retruspctiv study. J Gas troenterol 47: 586-595
10. Targher G, Byrne CD (2013) Clinical Review: Nonalco holic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98: 483-495
11. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G (2007) Prevalence of non alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212-1218
12. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M (2008) Non-alcoholic fatty liver dis ease is independently associated with an increased prevalence of chronic kidney disease and prolifera tive laser-treated retinopathy in type 2 diabetic pa tients. Diabetologia 51: 444-450
13. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R (2012) Meta-analysis: pioglitazone improves liver his tology and fibrosis in patients with non-alcoholic stea tohepatitis. Aliment Pharmacol Ther 35: 66-75
14. Sanyal AJ, Chalasani N, Kowdley Ky, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR (2010) Pio glitazone, vitamin E, or placebo for nonalcoholic stea tohepatitis. N Engl J Med 362: 1675-1685
15. Hasegawa T, Yoneda M, Nakamura K, Makino I, Ter ano A (2001) Plasma transforming growth factor-betal level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667-1672
16. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Ki hara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shi basaki M (2014) Effects of sodium-glucose cotrans porter 2 selective inhibitor ipragliflozin on hypergly caemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 66: 975-987
17. Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, Kushiyama A, Mon K, Matsunaga Y, Yamamotoya T, Kamata H, Asano T (2015) Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steato hepatitis in a rodent model with diabetes mellitus. Dia betol Metab Syndr 7: 104
18. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, Saito S, Nakajima A (2016) The Selective SGLT2 In hibitor Ipragliflozin Has a Thraputic Effect on Non alcoholic Steatohepatitis in Mice. PLoS One 11: eQ 146337
19. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in pa tients with nonalcoholic fatty liver disease. J Clin In vest 115: 1343-1351
20. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E. Thevenet J. Beaucamps C. Delalleau N. Popescu I. Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic al pha cells triggers glucagon secretion. Nat Med 21: 512-517
21. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fior entino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA (2014) Dapagliflozin improves muscle insulin sensitivity but enhances en dogenous glucose production. J Clin Invest 124: 509-514
22. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, Dc Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst Jj, Deacon CF, Gottesdiener KM, Wagner JA (2006) Effect of single oral doses of sitagliptin, a dipep tidyl peptidase-4 inhibitor, on incretin and plasma glu cose levels after an oral glucose tolerance test in pa tients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612-4619
23. Murai K, Katsuno T, Miyagawa J, Matsuo T, Ochi F, Tokuda M, Kusunoki Y, Miuchi M, Namba M (2014) Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, gluca gon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Drugs R D 14: 301-308
24. Baskol G, Baskol M, Kocer D (2007) Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 40: 776-780